Abstract: The present invention relates to the use of a dinQ-sRNA type I toxin-antitoxin systems for plasmid maintenance. An embodiment of the present invention relates to the use of the dinQ-sRNA type I toxin-antitoxin system for the manufacture of a plasmid selection system. In another embodiment of the present invention is the sRNA selected from the group consisting of agrA and agrB. Aspects of the present invention also relates to medical uses of the plasmid selection system.

Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosme (5hmC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.

Abstract: The invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of bladder cancer in biological samples (e.g., tissue samples, urine samples, urine sediments). In some embodiments, methods and biomarkers of the present invention find use in discriminating between bladder cancer, prostate cancer and renal epithelial tumors.

Abstract: The invention relates to medical monitoring apparatuses, methods, and computer programs for determining power or work as a function of time for individual myocardial segments based on strain and pressure measurements. Compared to prior art determinations of determination of mechanical power or work for individual segments, the invention is advantageous as it provides such determination solely from a pressure measurement or estimate and a measurement of strain, preferably by echocardiography, such as speckle tracking ultrasound imaging. This allows a fast, easy and non-invasive determination with high temporal and spatial resolution. A number of indices for segment work can be calculated which can be used as markers for the individual segment function as well as for a selection of patient for CRT.

Abstract: The invention relates to segmenting blood vessels in perfusion MR images, more particularly, the invention relates to automated vessel removal in identified tumor regions prior to tumor grading. Pixels from a perfusion related map from dynamic contrast enhancement (DCE) MR images are clustered into arterial pixels and venous pixels by e.g. a k-means class cluster analysis. The analysis applies parameters representing the degree to which the tissue entirely consists of blood (such as relative blood volume (rBV), peak enhancement (?R2max) and/or post first-pass enhancement level (?R2p)) and parameters representing contrast arrival time at the tissue (such as first moment of the area (fmAUC) and/or contrast arrival time (T0)). The artery and venous pixels are used to form a vessel mask. The invention also relates to a computer aided diagnostic (CAD) system for tumor grading, comprising automated tumor segmentation, vessel segmentation, and tumor grading.

Abstract: The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.

Abstract: An embodiment of the invention is to make possible a non-invasive grading of a tumor based on parameters determined from a frequency distribution (histogram) of values in a map representing cerebral blood volume (CBV) or cellular metabolism in the tumor. The method is especially applicable to brain tumors such as gliomas where histological grading is difficult. The invention provides a precise and consistent grading since it relies on values selected from the whole tumor (not just from hot spots); since it takes the diversity or heterogeneity of the vascularization into account by analyzing the frequency distribution (not just a mean value); and since it involves and allows for a more automated procedure wherein any subjective contributions from human operators is not critical to the resulting grading. CBV maps may be obtained by perfusion imaging using MRI or CT scanning. Cellular metabolism maps may be obtained from a glucose metabolism map obtained by positron emission tomography (PET).

Abstract: The present inventors here present a novel strategy for identification of RNA transcript variants and demonstrate that these can be correlated to disease states in mammals such as cancer. In particular, the transcript variants show prevalence and specificity to cancer, and thus also show clinical applicability in e.g. cancer diagnostics and prognostics, treatment and therapeutics. The present inventors have identified RNA transcript variants of VNN1 that can be used as biomarkers. The RNA transcript variant may also be used as biomarkers for diagnosing, prognosing, and/or monitoring a cancer.

Abstract: The invention provides a method, an image analysis software product, and a system for medical imaging analysis for estimating contrast agent extravasation in contrast agent based perfusion imaging such as MRI dynamic contrast enhanced (DCE) imaging, and in particular correction, compensation, or visualization of extravascular leakage of contrast agent in tumors. According to the invention, the effect of extravasation is directly manifested in the tail part of an observed, apparent residue function, R?(t), obtained directly by de-convoluting the expression C(t)=R?(t)Cp?(t) with the arterial input function (AIF). A leakage rate or extravasation constant is determined directly from the tail part of the determined apparent residue function.

Abstract: The invention relates to segmenting blood vessels in perfusion MR images, more particularly, the invention relates to automated vessel removal in identified tumor regions prior to tumor grading. Pixels from a perfusion related map from dynamic contrast enhancement (DCE) MR images are clustered into arterial pixels and venous pixels by e.g. a k-means class cluster analysis. The analysis applies parameters representing the degree to which the tissue entirely consists of blood (such as relative blood volume (rBV), peak enhancement (?R2max) and/or post first-pass enhancement level (?R2p)) and parameters representing contrast arrival time at the tissue (such as first moment of the area (fmAUC) and/or contrast arrival time (T0)). The artery and venous pixels are used to form a vessel mask. The invention also relates to a computer aided diagnostic (CAD) system for tumor grading, comprising automated tumor segmentation, vessel segmentation, and tumor grading.

Abstract: The invention relates to a method and a post-operative care unit for analysing and quantifying an ultrasound tissue Doppler imaging (TDI) signal from a transducer fastened on the myocardium to obtain a parameter indicating regional cardiac ischaemia or correlates with global hypokinetic heart function. This has the advantage over manually operated probes that it can be automated and used continuously over long time. According to the method, a TDI signal trace corresponding to at least one of tissue velocity, strain or strain rate is extracted and correlated with an electrocardiogram to define subsections within a cardiac cycle in the extracted trace corresponding to the early systolic phase and the post-systolic phase. Then, a velocity, strain or strain rate is read in at least the post-systolic phase of the extracted trace, and a parameter which is a function of one of these readings and which indicates ischaemia or global hypokinetic function is generated.

Abstract: The present invention relates to a microarray comprising a chimeric probe for an intergenic exon-to-exon junction of a fusion gene and at least two intragenic probes for a fusion gene partner of the fusion gene. The invention further relates to a method of detecting a fusion gene and a kit suitable for detecting fusion genes.

Abstract: The present invention relates to novel markers for hypermethylation of gene promoters in cancers. In particular the present invention relates to a method of determining whether a tumour is developing in the aero-digestive system, or whether a subject is relapsing after treatment of such a tumour. The method comprises determining the methylation level, the number of methylated CpG sites or the methylation state of CpG sites in a nucleic acid sequence in the promoter region, first exon or intron, of one or more genes selected from the group consisting of CNRIP1, MAL, FBN1, SPG20, SNCA, and INA. The method further relates to a diagnostic kit for detecting tumours in the aero-digestive tract.